Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia

Journal of Internal Medicine

Volumn 253, Issue 2, 2003, Pages 161-168

  De Sauvage Nolting, P R W ^a   Defesche, J C ^a   Buirma, R J A ^b   Hutten, B A ^a   Lansberg, P J ^c   Kastelein, J J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NV ORGANON   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cardiovascular disease; Familial hypercholesterolaemia; Lipids; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRATE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PREVALENCE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; RISK FACTORS;

EID: 0037322439     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01070.x     Document Type: Article

References (44)

1. Lansberg PJ, Tuzgol S, van de Ree MA, Defesche JC, Kastelein JJ. Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands. Ned Tijdschr Geneeskd 2000; 144: 1437-40.
2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
3. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, Inc., 2001; 2863-913.
4. Fouchier SW, Defesche JC, Umans-Eckenhausen MA, Kastelein JJ. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet 2001; 109: 602-15.
5. Thompson GR, Seed M, Niththyananthan S, McCarthy S, Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 1989; 9: I75-I80.
6. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998; 18: 309-15.
7. de Sauvage Nolting PRW, Buirma RJA, Hutten BA, Kastelein JJP. Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH). Atherosclerosis 2002; 164: 347-54.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
9. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991; 37: 1676-82.
10. Tate JR, Berg K, Couderc R et al. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a). Clin Chem Lab Med 1999; 37: 949-58.
11. Spaapen LJM, Waterval WAH, Bakker JA, Luijckx GJ, Vles JHS. Detection of hyperhomocysteinemia at premature cerebrovascular disease. Dutch Ass Clin Chem 1992; 17: 194-9.
12. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165-8.
13. Lippi G, Ruzzenente O, Brentegani C, Pierotti A, Guidi G. Evaluation of the analytical performances of a new fully automated commercial immunonephelometric assay for lipoprotein(a). Clin Chem Lab Med 1998; 36: 719-23.
14. De Bree A, Verschuren WM, Blom HJ, Graaf-Hess A, Trijbels FJ, Kromhout D. The homocysteine distribution: (mis)judging the burden. J Clin Epidemiol 2001; 54: 462-9.
15. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290-7.
16. Wittekoek ME, de Groot E, Prins MH, Trip MD, Buller HR, Kastelein JJ. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999; 146: 271-9.
17. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-12.
18. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2001; 87: 547-53.
19. Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 1997; 17: 3127-38.
20. Beaumont V, Jacotot B, Beaumont JL. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. Atherosclerosis 1976; 24: 441-50.
21. Yanagi K, Yamashita S, Kihara S et al. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis 1997; 132: 43-51.
22. Bertolini S, Cantafora A, Averna M et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000; 20: E41-E52.
23. Yamashita S, Kawamoto T, Ueyama Y et al. Relationship between LDL receptor activity and development of coronary heart disease in Japanese cases with heterozygous familial hypercholesterolemia. Artery 1987; 15: 24-43.
24. Smilde T, van Wissen S, Trip MD, Wollersheim H, Kastelein JJP, Stalenhoef A. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familail hypercholesterolemia. Clin Drug Invest 2000; 20: 67-79.
25. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995; 92: 290-5.
26. Real JT, Chaves FJ, Martinez-Uso I, Garcia-Garcia AB, Ascaso JF, Carmena R. Importance of HDL cholesterollevels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J 2001; 22: 465-71.
27. Gaudet D, Vohl MC, Perron P et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998; 97: 871-7.
28. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels, multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci 1989; 86: 4171-4.
29. Wiklund O, Angelin B, Olofsson SO et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360-3.
30. M Bewu AD Bhatnagar D et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991; 11: 940-6.
31. Real JT, Ascaso JF, Chaves FJ et al. Plasma Lp(a) values in familial hypercholesterolemia and its relation to coronary heart disease. Nutr Metab Cardiovasc Dis 1999; 9: 41-4.
32. Scholtz CL, Lingenhel A, Hillermann R et al. Lipoprotein(a) determination and risk of cardiovascular disease in South African patients with familial hypercholesterolaemia. S Afr Med J 2000; 90: 374-8.
33. Leus FR, Leerink CB, Prins J, van Rijn HJ. Influence of apolipoprotein(a) phenotype on lipoprotein(a) quantification; evaluation of three methods. Clin Biochem 1994; 27: 449-55.
34. Kraft HG, Lingenhel A, Kochl S et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 713-9.
35. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
36. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia, Circulation 1998; 97: 237-41.
37. Kawashiri M, Kajinami K, Nohara A et al. Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia. Am J Cardiol 2000; 86: 840-5.
38. Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol 1999; 83: 1330-3.
39. Smilde TJ, van den Berkmortel FW, Boers GH et al. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1998; 18: 1958-63.
40. Karjalainen A, Heikkinen J, Savolainen MJ, Backstrom AC, Kesaniemi YA. Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy. Arterioscler Thromb Vasc Biol 2000; 20: 1101-6.
41. Bowden JF, Pritchard PH, Hill JS, Frohlich JJ. Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1561-8.
42. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.
43. De Bree A, Verschuren WM, Blom HJ, Kromhout D, Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20-65 y. Am J Clin Nutr 2001; 73: 1027-33.
44. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994; 236: 633-41.